Repligen to Attend Three Investor Conferences in September
ByAinvest
Friday, Aug 22, 2025 7:32 am ET1min read
RGEN--
At the Wells Fargo Healthcare Conference, scheduled from September 3 to 5 in Boston, CEO Olivier Loeillot will join an analyst discussion on September 4 at 8:00 a.m. ET. The Deutsche Bank Healthcare Summit, taking place on September 10 and 11 in New York City, will see CFO Jason Garland participate in 1x1 meetings on September 10. Finally, at the Bank of America Global Healthcare Conference, from September 23 to 25 in London, CEO Olivier Loeillot will participate in an analyst discussion on September 25 at 6:35 a.m. ET. Live webcasts of these events will be available on Repligen’s Investor Relations website.
Repligen Corporation is a global life sciences company focused on developing and commercializing innovative bioprocessing technologies and systems. These technologies aim to enhance the efficiency of manufacturing biological drugs, primarily for biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. The company's headquarters are located in Waltham, Massachusetts, with manufacturing sites across several countries, including the United States, Estonia, France, Germany, Ireland, the Netherlands, and Sweden.
For more information about Repligen Corporation, visit their website at [Repligen Corporation](https://www.repligen.com) and follow them on LinkedIn.
References:
[1] https://www.stocktitan.net/news/RGEN/repligen-corporation-to-present-at-upcoming-september-jzxm1p0l9340.html
[2] https://www.biospace.com/press-releases/restart-life-sciences-provides-corporate-update-on-strategy-and-growth-initiatives
Repligen Corporation, a life sciences company, announced its participation in three investor conferences. Olivier Loeillot, CEO, will present at the Wells Fargo Healthcare Conference on September 4 and the Bank of America Global Healthcare Conference on September 25. Jason Garland, CFO, will participate in 1x1 meetings at the Deutsche Bank Healthcare Summit on September 10. Live webcasts of the presentations will be available on Repligen's Investor Relations website.
Repligen Corporation (NASDAQ: RGEN), a leading bioprocessing technology company in life sciences, has announced its participation in three significant investor conferences in September 2025. The company will be presenting at the Wells Fargo Healthcare Conference, the Deutsche Bank Healthcare Summit, and the Bank of America Global Healthcare Conference. Live webcasts of the presentations will be available on Repligen's Investor Relations website.At the Wells Fargo Healthcare Conference, scheduled from September 3 to 5 in Boston, CEO Olivier Loeillot will join an analyst discussion on September 4 at 8:00 a.m. ET. The Deutsche Bank Healthcare Summit, taking place on September 10 and 11 in New York City, will see CFO Jason Garland participate in 1x1 meetings on September 10. Finally, at the Bank of America Global Healthcare Conference, from September 23 to 25 in London, CEO Olivier Loeillot will participate in an analyst discussion on September 25 at 6:35 a.m. ET. Live webcasts of these events will be available on Repligen’s Investor Relations website.
Repligen Corporation is a global life sciences company focused on developing and commercializing innovative bioprocessing technologies and systems. These technologies aim to enhance the efficiency of manufacturing biological drugs, primarily for biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. The company's headquarters are located in Waltham, Massachusetts, with manufacturing sites across several countries, including the United States, Estonia, France, Germany, Ireland, the Netherlands, and Sweden.
For more information about Repligen Corporation, visit their website at [Repligen Corporation](https://www.repligen.com) and follow them on LinkedIn.
References:
[1] https://www.stocktitan.net/news/RGEN/repligen-corporation-to-present-at-upcoming-september-jzxm1p0l9340.html
[2] https://www.biospace.com/press-releases/restart-life-sciences-provides-corporate-update-on-strategy-and-growth-initiatives
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet